Source:http://linkedlifedata.com/resource/pubmed/id/11932959
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
2002-4-4
|
pubmed:abstractText |
The current work evaluated the effect of the CYP3A inhibitor ketoconazole on the oral absorption and first-pass metabolism of cyclosporine administered as the SangCyA formulation. Groups of 6 male Sprague-Dawley rats were administered SangCyA (5 and 15 mg/kg) by oral gavage alone and with ketoconazole (30 mg/kg). Blood cyclosporine levels were measured over 6 h, encompassing the cyclosporine absorption window. A significant vehicle effect on SangCyA absorption was observed. Comparing a 15 mg/kg dose, cyclosporine C(max) (mean+/-SD 1.12+/-0.16 microg/ml) and AUC(0-6) (5.34+/-0.71 microg h/ml) were 50% lower when propylene glycol was used as gavage vehicle instead of saline (2.19+/-0.94 microg/ml and 9.52+/-2.52 microg h/ml, respectively). Coefficients-of-variation for these parameters were halved in the propylene glycol vehicle however T(max) was unaffected. Ketoconazole increased cyclosporine C(max) and AUC(0-6) by 50-60%, regardless of the vehicle or the cyclosporine dose, without altering T(max) (2-3 h). The small effect of ketoconazole suggests that CYP3A-mediated intestinal and first-pass hepatic metabolism are minor determinants of cyclosporine oral bioavailability in rats.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antifungal Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclosporine,
http://linkedlifedata.com/resource/pubmed/chemical/Immunosuppressive Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Ketoconazole,
http://linkedlifedata.com/resource/pubmed/chemical/Pharmaceutical Vehicles
|
pubmed:status |
MEDLINE
|
pubmed:month |
Mar
|
pubmed:issn |
0142-2782
|
pubmed:author | |
pubmed:copyrightInfo |
Copyright 2002 John Wiley & Sons, Ltd.
|
pubmed:issnType |
Print
|
pubmed:volume |
23
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
53-7
|
pubmed:dateRevised |
2010-11-18
|
pubmed:meshHeading |
pubmed-meshheading:11932959-Animals,
pubmed-meshheading:11932959-Antifungal Agents,
pubmed-meshheading:11932959-Area Under Curve,
pubmed-meshheading:11932959-Biological Availability,
pubmed-meshheading:11932959-Chromatography, High Pressure Liquid,
pubmed-meshheading:11932959-Cyclosporine,
pubmed-meshheading:11932959-Drug Interactions,
pubmed-meshheading:11932959-Immunosuppressive Agents,
pubmed-meshheading:11932959-Intestinal Absorption,
pubmed-meshheading:11932959-Ketoconazole,
pubmed-meshheading:11932959-Male,
pubmed-meshheading:11932959-Pharmaceutical Vehicles,
pubmed-meshheading:11932959-Rats,
pubmed-meshheading:11932959-Spectrophotometry, Ultraviolet
|
pubmed:year |
2002
|
pubmed:articleTitle |
Minimal effect of ketoconazole on cyclosporine (SangCyA) oral absorption and first-pass metabolism in rats: evidence of a significant vehicle effect on SangCyA absorption.
|
pubmed:affiliation |
AvMax Inc., South San Francisco, CA 94080, USA.
|
pubmed:publicationType |
Journal Article
|